← Eichor
Study identifier: NCT06372613 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Association Between LRG and Histologic Remission in Ulcerative Colitis

Condition: Ulcerative Colitis in Histologic Remission  ·  Sponsor: Showa Inan General Hospital

PhaseN/A
Planned participants100
Who can joinAll sexes, 20 Years to 90 Years
Healthy volunteersNo

About this study

We attempt to clarify the serum leucine-rich α 2-glycoprotein (LRG) level which can predict histologic remission in ulcerative colitis patients in this study. Colonoscopy with histology will be performed when histologic remission is predicted, irrespective of symptoms or serum LRG values. Serum LRG levels are analyzed by an enzyme-linked immunosorbent assay.

This description comes directly from the study's public registry record.

Talk to the study team

Akia Horiuchi  ·  09021684311  ·  horiuchi.akira@sihp.jp

Always discuss trial participation with your own doctor first.

Locations (1)

Showa Inan General HospitalKomagane, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06372613